

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or R

New England Journal of Medicine

380, 1726-1737

DOI: [10.1056/nejmoa1817226](https://doi.org/10.1056/nejmoa1817226)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging protein kinase inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 133-152.	1.0	20
2	SOHO State of the Art Updates and Next Questions: T-Cellâ€“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€“Modified T Cells and Bispecific T-Cellâ€“Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.2	18
6	Multitargeted CAR T-cell therapy in multiple myeloma. <i>Lancet Haematology</i> , 2019, 6, e494-e495.	2.2	3
7	Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, e6.	13.9	3
8	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 997.	1.0	45
9	B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1143-1156.	1.4	69
10	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. <i>Frontiers in Immunology</i> , 2019, 10, 1613.	2.2	70
11	Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. <i>Antibodies</i> , 2019, 8, 41.	1.2	90
12	CAR T-Cell Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 923.	3.8	10
13	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 186, 807-819.	1.2	14
14	The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. <i>Cellular Immunology</i> , 2019, 345, 103964.	1.4	18
15	CAR-T â€œthe living drugsâ€; immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
16	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	3.3	47
17	Recent updates on CAR T clinical trials for multiple myeloma. <i>Molecular Cancer</i> , 2019, 18, 154.	7.9	71
18	BAFF inhibition in SLEâ€“Is tolerance restored?. <i>Immunological Reviews</i> , 2019, 292, 102-119.	2.8	38
21	Industry updates from the field of stem cell research and regenerative medicine in May 2019. <i>Regenerative Medicine</i> , 2019, 14, 815-822.	0.8	0
22	Relapsed refractory multiple myeloma: a comprehensive overview. <i>Leukemia</i> , 2019, 33, 2343-2357.	3.3	90
23	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 855.	1.1	5

#	ARTICLE	IF	CITATIONS
24	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	15.2	400
25	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019, 3, 2487-2490.	2.5	35
26	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
27	The Future of Cellular Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S102-S105.	0.2	0
28	Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019, 134, 1585-1597.	0.6	209
29	CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms. <i>BioDrugs</i> , 2019, 33, 647-659.	2.2	20
30	What is new in the treatment of Waldenstrom macroglobulinemia?. <i>Leukemia</i> , 2019, 33, 2555-2562.	3.3	19
31	Novel targets for the treatment of relapsing multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 481-496.	1.0	25
32	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 59.	6.9	127
33	Anti-BCMA CAR T cells for MM. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 465-465.	12.5	3
34	CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon. <i>Blood Science</i> , 2019, 1, 156-160.	0.4	3
35	CAR T-cell therapy: is it prime time in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 260-265.	0.9	17
36	Precision medicine for human cancers with Notch signaling dysregulation (Review). <i>International Journal of Molecular Medicine</i> , 2020, 45, 279-297.	1.8	105
37	Cytokine release syndrome: a primer for generalists. <i>Adverse Drug Reaction Bulletin</i> , 2019, 319, 1235-1238.	0.6	0
38	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	2.5	133
39	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3248-3260.	2.5	76
40	Teaming up for CAR-T cell therapy. <i>Haematologica</i> , 2019, 104, 2335-2336.	1.7	7
41	Trispecific antibodies offer a third way forward for anticancer immunotherapy. <i>Nature</i> , 2019, 575, 450-451.	13.7	27

#	ARTICLE	IF	CITATIONS
42	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
43	Cardiotoxicity of Immune Therapy. <i>Cardiology Clinics</i> , 2019, 37, 385-397.	0.9	54
44	Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. <i>Journal of Oncology</i> , 2019, 2019, 1-10.	0.6	22
45	Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2019, 11, 2009.	1.7	20
46	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3153-3163.	1.2	78
47	Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. <i>Cancers</i> , 2019, 11, 2024.	1.7	12
48	Chimeric antigen receptor T cell therapies for multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 120.	6.9	29
49	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
50	<p>Cytokine Release Syndrome: Current Perspectives</p>. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 43-52.	2.7	116
51	Is autologous stem cell transplantation still relevant for multiple myeloma?. <i>Current Opinion in Hematology</i> , 2019, 26, 386-391.	1.2	4
52	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6223.	1.8	88
53	Current status and hurdles for CAR-T cell immune therapy. <i>Blood Science</i> , 2019, 1, 148-155.	0.4	5
54	Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. <i>BMJ Case Reports</i> , 2019, 12, e231314.	0.2	0
55	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
56	Treatment Options for Triple-class Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 1-7.	0.2	73
57	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. , 2020, 205, 107419.		81
58	CAR Tâ€Cell Therapy in Hematologic Malignancies: A Voyage in Progress. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 112-122.	2.3	111
59	Adenoâ€Associated Viral Vectors for Homologyâ€Directed Generation of CARâ€T Cells. <i>Biotechnology Journal</i> , 2020, 15, e1900286.	1.8	9

#	ARTICLE	IF	CITATIONS
60	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e7-e15.	2.0	16
61	Future prospects of chimeric antigen receptor Tâ€cell therapy for multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e72.	0.6	0
62	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <i>Blood Reviews</i> , 2020, 39, 100616.	2.8	43
63	CART manufacturing process and reasons for academy-pharma collaboration. <i>Immunology Letters</i> , 2020, 217, 39-48.	1.1	9
64	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 1541-1554.	3.2	79
65	Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells. <i>American Journal of Hematology</i> , 2020, 95, E20-E23.	2.0	13
66	The microenvironment in myeloma. <i>Current Opinion in Oncology</i> , 2020, 32, 170-175.	1.1	45
67	Limited treatment options in refractory multiple myeloma: promising therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 31-44.	1.1	5
68	Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. <i>Haematologica</i> , 2020, 105, e138-e140.	1.7	5
69	Current challenges and emerging opportunities of CAR-T cell therapies. <i>Journal of Controlled Release</i> , 2020, 319, 246-261.	4.8	78
70	Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. <i>MAbs</i> , 2020, 12, 1688616.	2.6	71
71	Antiâ€B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
72	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 29-41.	1.3	17
73	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	5.1	544
75	Bispecific antibodies in cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 9-16.	3.3	59
76	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. <i>Leukemia</i> , 2020, 34, 21-34.	3.3	117
77	B cell maturation antigenâ€specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A metaâ€analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	1.1	41
78	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1

#	ARTICLE	IF	CITATIONS
79	Advances in chimeric antigen receptor T cells. <i>Current Opinion in Hematology</i> , 2020, 27, 368-377.	1.2	24
80	Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. <i>Cancer Immunology Research</i> , 2020, 8, 1485-1495.	1.6	19
81	Immunotherapy in multiple myeloma: when, where, and for who?. <i>Current Opinion in Oncology</i> , 2020, 32, 664-671.	1.1	5
82	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. <i>Molecular Therapy</i> , 2020, 28, 2320-2339.	3.7	194
83	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 979-992.	0.4	11
84	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, 94.	2.8	178
85	Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. <i>Cancers</i> , 2020, 12, 2885.	1.7	23
86	Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells. <i>Scientific Reports</i> , 2020, 10, 17884.	1.6	14
88	Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation. <i>Immuno-Oncology Technology</i> , 2020, 7, 15-22.	0.2	3
89	CAR T cell therapy. <i>Immunological Medicine</i> , 2021, 44, 69-73.	1.4	4
90	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
91	Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2166.	1.0	25
92	Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. <i>Clinical and Translational Immunology</i> , 2020, 9, e1147.	1.7	7
93	<p></p>Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection<p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6405-6416.	1.0	12
94	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. <i>Experimental Hematology</i> , 2020, 88, 7-14.e3.	0.2	21
95	Actors on the Scene: Immune Cells in the Myeloma Niche. <i>Frontiers in Oncology</i> , 2020, 10, 599098.	1.3	51
96	Introduction to "Immunotherapies for Multiple Myeloma". <i>Pharmaceuticals</i> , 2020, 13, 396.	1.7	4
97	Induction therapy before autologous HSCT: a proper preparation pays off?. <i>Lancet Haematology</i> , the, 2020, 7, e852-e853.	2.2	0

#	ARTICLE	IF	CITATIONS
98	In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. <i>Nature Communications</i> , 2020, 11, 6080.	5.8	176
99	Risk and Response-Adapted Treatment in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3497.	1.7	10
100	CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. <i>Journal of Clinical Medicine</i> , 2020, 9, 3577.	1.0	21
101	The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. <i>Nature Biotechnology</i> , 2020, 38, 1387-1394.	9.4	16
102	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 164.	6.9	88
103	Recent Advances in the Treatment of Patients with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3576.	1.7	22
104	Future of CAR T cells in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 272-279.	0.9	22
105	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. <i>Genes</i> , 2020, 11, 1453.	1.0	2
106	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.4	34
107	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 1362.	1.3	45
108	Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 724-735.	0.2	5
109	Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. <i>JAMA Neurology</i> , 2020, 77, 1536.	4.5	68
110	Antibody-drug conjugates for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 889-901.	1.4	15
111	Multiple myeloma: the (r)evolution of current therapy and a glance into future. <i>Haematologica</i> , 2020, 105, 2358-2367.	1.7	73
112	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	2.5	20
113	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3794-3804.	0.8	235
114	B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5192.	1.8	24
115	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. <i>Seminars in Hematology</i> , 2020, 57, 83-91.	1.8	5

#	ARTICLE	IF	CITATIONS
116	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11
117	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	25
118	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1243.	1.3	63
119	A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 73.	1.3	1
120	What is the future of immunotherapy in multiple myeloma?. <i>Blood</i> , 2020, 136, 2491-2497.	0.6	22
121	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958.	1.0	16
122	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	1.7	92
123	Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells. <i>Cancers</i> , 2020, 12, 2117.	1.7	7
124	Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfectd with chronic hepatitis B virus. , 2020, 8, e000927.		23
125	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.	2.5	162
126	Chimeric Antigen Receptor T Cells: Clinical Applications, Advances and Challenges. , 2020, , 319-333.		1
127	Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 371-377.	0.6	8
128	Targeting NF- κ B Signaling for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2203.	1.7	24
129	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 607571.	1.3	0
130	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8000.	1.8	25
132	Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 11, a034900.	2.9	0
133	<p>Immunotherapeutic and Targeted Approaches in Multiple Myeloma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 201-215.	2.7	14
134	Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. <i>Future Oncology</i> , 2020, 16, 2783-2798.	1.1	12

#	ARTICLE	IF	CITATIONS
135	AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. <i>Blood Advances</i> , 2020, 4, 4180-4194.	2.5	29
136	Molecular Pathways Engaged by Immunomodulatory Agents in Monoclonal Gammopathy-Associated Pure Red Cell Aplasia Rescue. <i>Frontiers in Oncology</i> , 2020, 10, 1490.	1.3	0
137	BCMA-targeted immunotherapy for multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 125.	6.9	108
138	The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen. <i>Frontiers in Oncology</i> , 2020, 10, 1617.	1.3	9
139	Emerging immunotherapies in multiple myeloma. <i>BMJ, The</i> , 2020, 370, m3176.	3.0	62
140	Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. <i>Blood Advances</i> , 2020, 4, 4538-4549.	2.5	67
141	Immune-based therapies in the management of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 84.	2.8	38
142	Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 3259-3262.	0.6	1
143	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	1.9	17
144	The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. <i>Blood Advances</i> , 2020, 4, 4195-4207.	2.5	39
145	Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2523.	1.7	27
146	Immune–based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. <i>HemaSphere</i> , 2020, 4, e423.	1.2	4
147	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
148	Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6028-6038.	3.2	20
149	The pharmacist’s role in chimeric antigen receptor T cell therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1725-1731.	0.5	3
150	Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 544754.	1.6	12
151	Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. <i>Frontiers in Oncology</i> , 2020, 10, 608916.	1.3	13
152	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. <i>Cell Chemical Biology</i> , 2021, 28, 802-812.e6.	2.5	25

#	ARTICLE	IF	CITATIONS
153	Recommendations on the management of multiple myeloma in 2020. <i>Acta Clinica Belgica</i> , 2020, , 1-17.	0.5	1
154	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
156	Practical aspects of building a new immunotherapy program: the future of cell therapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 579-584.	0.9	2
157	The Application of CAR-T Cells in Haematological Malignancies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 34.	1.0	19
158	Emerging agents and regimens for multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 150.	6.9	55
159	Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 449-457.	1.3	21
160	Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3554.	1.0	4
161	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. <i>Haematologica</i> , 2020, 106, 173-184.	1.7	25
162	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. <i>Leukemia</i> , 2020, 34, 2688-2703.	3.3	52
163	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , 2020, 12, 1075.	1.7	57
164	Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 799-805.	2.0	6
165	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1559-1566.	2.0	6
166	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
167	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
168	Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. <i>Journal of Translational Medicine</i> , 2020, 18, 191.	1.8	19
169	BiTEing the Tumor. <i>Journal of Clinical Oncology</i> , 2020, 38, 2077-2079.	0.8	8
170	The BiTE (bispecific T cell engager) platform: Development and future potential of a targeted immunooncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
171	Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment. <i>Bone Marrow Transplantation</i> , 2020, 55, 2215-2218.	1.3	8

#	ARTICLE	IF	CITATIONS
172	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	1.3	66
173	Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12910.	1.3	25
174	New drugs in early development for treating multiple myeloma: all that glitters is not gold. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 989-1004.	1.9	4
175	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
176	Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. <i>Biomarker Research</i> , 2020, 8, 14.	2.8	21
177	The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 676.	1.3	3
178	Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1907-1915.	0.8	4
179	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. <i>Cancers</i> , 2020, 12, 1333.	1.7	9
180	Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2324-2334.	0.6	6
181	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
182	Cost of decentralized CAR T-cell production in an academic nonprofit setting. <i>International Journal of Cancer</i> , 2020, 147, 3438-3445.	2.3	45
183	Development of CAR-T cell therapies for multiple myeloma. <i>Leukemia</i> , 2020, 34, 2317-2332.	3.3	68
184	Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. <i>Molecular Therapy</i> , 2020, 28, 2237-2251.	3.7	50
185	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
186	Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e93.	0.6	0
187	Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1589-1596.	2.0	6
188	The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 827.	1.3	23
189	Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield. <i>Leukemia and Lymphoma</i> , 2020, 61, 1777-1779.	0.6	1

#	ARTICLE	IF	CITATIONS
190	Targeted Therapy With Immunoconjugates for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1155.	2.2	38
191	Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e752-e768.	0.2	28
192	The Struggle Is Real: Practice Patterns for the “Myelennial” Generation. <i>JCO Oncology Practice</i> , 2020, 16, 17-18.	1.4	0
193	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 860.	1.3	35
194	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1128.	2.2	29
195	BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 1473.	1.7	40
196	Chimeric antigen receptor T-cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689.	1.1	25
197	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
198	Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2020, 189, e126-e130.	1.2	13
199	Immunotherapy in Multiple Myeloma. <i>Cells</i> , 2020, 9, 601.	1.8	27
200	Multiple myeloma: 2020 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 548-567.	2.0	507
201	T cell-engaging therapies – BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	12.5	296
202	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. <i>Cancers</i> , 2020, 12, 842.	1.7	21
203	Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 191.	2.2	30
204	Prospects and challenges for use of CAR T cell therapies in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 503-516.	1.4	37
205	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	0.8	12
206	Next-generation CAR T cells to overcome current drawbacks. <i>International Journal of Hematology</i> , 2020, 114, 532-543.	0.7	7
208	Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. <i>Leukemia</i> , 2020, 34, 2704-2707.	3.3	21

#	ARTICLE	IF	CITATIONS
209	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. , 2020, 8, e000286.		11
210	CAR-T cells: the Chinese experience. Expert Opinion on Biological Therapy, 2020, 20, 1293-1308.	1.4	4
211	Recent advances in CAR-T cell engineering. Journal of Hematology and Oncology, 2020, 13, 86.	6.9	192
212	Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. Journal of Clinical Medicine, 2020, 9, 2142.	1.0	13
213	Cancer immunoediting and immune dysregulation in multiple myeloma. Blood, 2020, 136, 2731-2740.	0.6	84
214	Improving the Odds. Biology of Blood and Marrow Transplantation, 2020, 26, e173-e174.	2.0	1
215	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 2020, 136, 925-935.	0.6	158
216	CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Advances, 2020, 4, 2899-2911.	2.5	36
217	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438.	0.6	37
218	BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. Journal of Immunotherapy, 2020, 43, 175-188.	1.2	25
219	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 146-154.	2.6	114
220	Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. International Journal of Hematology, 2020, 111, 519-529.	0.7	8
221	CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nature Communications, 2020, 11, 798.	5.8	43
222	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 2020, 12, 194.	2.0	40
223	The safety of current and emerging therapies for multiple myeloma. Expert Opinion on Drug Safety, 2020, 19, 269-279.	1.0	6
224	CAR-T cells in multiple myeloma: current status. Memo - Magazine of European Medical Oncology, 2020, 13, 43-49.	0.3	4
225	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020, 126, 1837-1855.	2.0	20
226	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biology of Blood and Marrow Transplantation, 2020, 26, 1071-1076.	2.0	63

#	ARTICLE	IF	CITATIONS
227	Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. <i>International Journal of Hematology</i> , 2020, 111, 512-518.	0.7	7
228	CAR T cells: continuation in a revolution of immunotherapy. <i>Lancet Oncology, The</i> , 2020, 21, e168-e178.	5.1	204
229	Approaches to Treating Multiple Myeloma, Now and Moving Forward. <i>JCO Oncology Practice</i> , 2020, 16, 15-16.	1.4	4
230	B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. <i>Leukemia</i> , 2020, 34, 985-1005.	3.3	253
231	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. <i>Leukemia</i> , 2020, 34, 2150-2162.	3.3	45
232	Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. <i>Nature Communications</i> , 2020, 11, 283.	5.8	74
233	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. <i>American Journal of Kidney Diseases</i> , 2020, 76, 63-71.	2.1	74
234	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>International Journal of Hematology</i> , 2020, 111, 530-534.	0.7	5
235	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, 5-14.	1.4	28
236	CAR T and CAR NK cells in multiple myeloma: Expanding the targets. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101141.	0.7	38
237	Monitoring minimal residual disease in the bone marrow using next generation sequencing. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101149.	0.7	9
238	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. <i>Briefings in Functional Genomics</i> , 2020, 19, 175-182.	1.3	59
239	Modern treatments and future directions for newly diagnosed multiple myeloma patients. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101151.	0.7	6
240	Enhancing cancer immunotherapy with nanomedicine. <i>Nature Reviews Immunology</i> , 2020, 20, 321-334.	10.6	506
241	Presence of soluble and cell surface B cell maturation antigen in systemic light chain amyloidosis and its modulation by gamma secretase inhibition. <i>American Journal of Hematology</i> , 2020, 95, E110-E113.	2.0	10
242	Antibody-based targeting of BCMA in multiple myeloma. <i>Lancet Oncology, The</i> , 2020, 21, 186-187.	5.1	2
243	Venetoclax: the first anti-myeloma agent with a reliable biomarker. <i>British Journal of Haematology</i> , 2020, 189, 1003-1005.	1.2	6
244	Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?. <i>Cancers</i> , 2020, 12, 1045.	1.7	11

#	ARTICLE	IF	CITATIONS
245	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 636.	1.3	24
246	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. <i>Cells</i> , 2020, 9, 768.	1.8	27
247	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	2.3	10
248	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1923-1937.	1.2	14
249	Cancer immunotherapy: Current applications and challenges. <i>Cancer Letters</i> , 2020, 480, 1-3.	3.2	19
250	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	13.5	247
251	Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Realâ€life outcomes of daratumumab treatment. <i>European Journal of Haematology</i> , 2020, 105, 196-202.	1.1	10
252	Car-T Treatment for Hematological Malignancies. <i>Journal of Investigative Medicine</i> , 2020, 68, 956-964.	0.7	20
253	DNT Cell-based Immunotherapy: Progress and Applications. <i>Journal of Cancer</i> , 2020, 11, 3717-3724.	1.2	23
254	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. <i>Clinical and Experimental Medicine</i> , 2020, 20, 469-480.	1.9	8
255	Implantable Therapeutic Reservoir Systems for Diverse Clinical Applications in Large Animal Models. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000305.	3.9	13
256	Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. <i>Cells</i> , 2020, 9, 983.	1.8	10
258	Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. <i>Medicine (United States)</i> , 2020, 99, e19739.	0.4	2
259	Antibodyâ€based immunotherapy for treatment of immunoglobulin lightâ€chain amyloidosis. <i>British Journal of Haematology</i> , 2020, 191, 673-681.	1.2	3
260	Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. <i>Blood</i> , 2020, 135, 668-679.	0.6	7
261	A T-cellâ€redirecting bispecific G-proteinâ€coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. <i>Blood</i> , 2020, 135, 1232-1243.	0.6	82
262	Chimeric antigen receptorâ€T cells with cytokine neutralizing capacity. <i>Blood Advances</i> , 2020, 4, 1419-1431.	2.5	27
263	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146

#	ARTICLE	IF	CITATIONS
264	Chimeric antigen receptor T cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	1.1	19
265	Revisiting the CAR T Cell Combination strategies to enhance CAR T cell effectiveness. <i>Blood Reviews</i> , 2021, 45, 100695.	2.8	22
266	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. <i>Leukemia</i> , 2021, 35, 752-763.	3.3	52
267	Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 90-113.	2.7	24
268	Developing cell therapies as drug products. <i>British Journal of Pharmacology</i> , 2021, 178, 262-279.	2.7	6
269	Conventional T cell therapies pave the way for novel Treg therapeutics. <i>Cellular Immunology</i> , 2021, 359, 104234.	1.4	2
270	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	3.7	48
271	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 9-19.	1.3	22
272	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
273	Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. <i>Annual Review of Medicine</i> , 2021, 72, 365-382.	5.0	34
274	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 202-209.	1.3	6
275	Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor T Cells in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 716-727.	2.3	49
276	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103096.	2.0	10
277	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	4.2	7
278	Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 33-43.	1.1	5
279	Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 21-34.	0.2	4
280	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy—what are we doing; where are we going?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 627-637.	1.4	25
281	Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value. <i>Human Gene Therapy</i> , 2021, 32, 433-445.	1.4	5

#	ARTICLE	IF	CITATIONS
282	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. <i>Neuro-Oncology Practice</i> , 2021, 8, 259-265.	1.0	3
283	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	6.3	196
284	Focus on monoclonal antibodies targeting B cell maturation antigen (BCMA) in multiple myeloma: update 2021. <i>British Journal of Haematology</i> , 2021, 193, 705-722.	1.2	18
285	Chimeric antigen receptor (CAR) natural killer (NK) cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	1.2	61
286	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	0.8	98
287	Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.6	1
288	Engineering precision therapies: lessons and motivations from the clinic. <i>Synthetic Biology</i> , 2021, 6, ysaa024.	1.2	5
289	Co-expression of IL7 and PH20 promote anti-GPC3 CAR T tumour suppressor activity in vivo and in vitro. <i>Liver International</i> , 2021, 41, 1033-1043.	1.9	17
290	Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. <i>Molecular Therapy</i> , 2021, 29, 702-717.	3.7	60
291	Cytokine syndromes associated with hematopoietic cellular therapy. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.6	1
292	CAR T cell therapies for patients with multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 71-84.	12.5	156
293	The Role of Targeted Therapy in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2021, , 1-15.	0.1	0
294	Nanobody Conjugates for Targeted Cancer Therapy and Imaging. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110101.	0.8	19
295	CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity. , 2021, , 915-928.		0
296	Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. <i>Military Medical Research</i> , 2021, 8, 9.	1.9	4
297	Allogeneic CAR Cell Therapy—More Than a Pipe Dream. <i>Frontiers in Immunology</i> , 2020, 11, 618427.	2.2	64
298	Recent advances and discoveries in the mechanisms and functions of CAR T cells. <i>Nature Reviews Cancer</i> , 2021, 21, 145-161.	12.8	436
299	Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T cell therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 5832-5847.	2.0	2

#	ARTICLE	IF	CITATIONS
300	An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opinion on Biological Therapy, 2021, 21, 1025-1034.	1.4	4
301	Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications, 2021, 28, 100414.	0.7	1
302	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 1096.	1.8	25
303	Neurologic complications associated with CAR T-cell therapy. , 2021, , 381-388.		0
304	Latest Developments in Cellular Therapy for Multiple Myeloma. Oncology & Hematology Review, 2021, 16, 111.	0.2	1
305	Nanomaterials for T-cell cancer immunotherapy. Nature Nanotechnology, 2021, 16, 25-36.	15.6	191
306	Potency analysis of cellular therapies: the role of molecular assays. , 2021, , 49-70.		0
307	Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy. , 2021, 18, .		0
308	Treatment and resistance of glioblastoma to CAR T-cell immunotherapies. , 2021, , 453-471.		0
309	Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences, 2021, 18, 1786-1797.	1.1	20
310	A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 137, 2890-2901.	0.6	100
311	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Frontiers in Oncology, 2020, 10, 606368.	1.3	23
313	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia, 2021, 35, 2346-2357.	3.3	28
314	Multiple myeloma. Lancet, The, 2021, 397, 410-427.	6.3	349
315	Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato, 2021, 2, 89-102.	0.2	1
316	CAR-T Therapy, the End of a Chapter or the Beginning of a New One?. Cancers, 2021, 13, 853.	1.7	5
317	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Frontiers in Immunology, 2021, 12, 611366.	2.2	41
318	Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. Journal of Medical Case Reports, 2021, 15, 90.	0.4	6

#	ARTICLE	IF	CITATIONS
319	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 23.	2.8	31
320	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 618387.	2.2	38
321	Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19⁺ Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 499-513.	0.8	5
322	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. <i>Annals of Hematology</i> , 2021, 100, 1537-1546.	0.8	7
323	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.2	2
326	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 456-466.	0.8	21
327	Vaccination as Immunotherapy in Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 433-443.	0.8	8
328	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. <i>Nature Medicine</i> , 2021, 27, 616-619.	15.2	140
329	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.2	4
330	Cancer therapy-induced hyponatremia: A case-illustrated review. <i>Journal of Onco-Nephrology</i> , 2021, 5, 70-78.	0.3	7
331	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
332	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <i>Nature Communications</i> , 2021, 12, 868.	5.8	173
333	Immunogenicity of CAR T cells in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 379-393.	12.5	128
334	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1642-1650.	1.3	14
335	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 608485.	2.2	4
336	Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2021, 96, 455-461.	2.0	35
337	Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 620596.	2.2	12
338	The Application of Nanobody in CAR-T Therapy. <i>Biomolecules</i> , 2021, 11, 238.	1.8	44

#	ARTICLE	IF	CITATIONS
339	Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 632937.	2.2	12
340	Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins. <i>Molecular Therapy</i> , 2021, 29, 718-733.	3.7	13
341	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. <i>Hemato</i> , 2021, 2, 116-130.	0.2	2
342	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111
343	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
344	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1568.	1.7	21
345	A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e346.	1.7	35
346	Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2021, 11, 44.	2.8	4
347	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021, 11, 45.	2.8	24
348	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
349	Cytokine Release Syndrome Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 119-125.	1.0	25
350	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2052-2063.	0.6	16
351	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. <i>British Journal of Haematology</i> , 2021, 193, 851-855.	1.2	6
352	Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 273.e1-273.e5.	0.6	4
353	Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 362-376.	1.3	23
354	A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. <i>Blood Advances</i> , 2021, 5, 1291-1304.	2.5	32
355	In vivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	2.0	14
356	Phase I Clinical Trials in Adoptive T-Cell Therapies. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2021, 70, 815-834.	0.5	4

#	ARTICLE	IF	CITATIONS
357	TAM-ing the CIAâ€”Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia. <i>Frontiers in Oncology</i> , 2021, 11, 627223.	1.3	3
358	How to Treat High-Risk Myeloma at Diagnosis and Relapse. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 291-309.	1.8	27
359	Chimeric Antigen Receptor T Cells for Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 112-118.	1.0	4
360	Chimeric Antigen Receptorâ€”Modified Immune Effector Cell Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 90-91.	1.0	0
361	Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. <i>Stem Cell Research and Therapy</i> , 2021, 12, 217.	2.4	14
362	Chimeric antigen receptor T cell therapy in oncology â€” Pipeline at a glance: Analysis of the ClinicalTrials.gov database. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103239.	2.0	21
363	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	5.1	136
364	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	1.2	24
365	Boosting Immunity against Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1221.	1.7	8
366	The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 609421.	2.2	38
367	Neurotoxicity Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 126-133.	1.0	7
368	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€”. <i>Annals of Oncology</i> , 2021, 32, 309-322.	0.6	316
369	Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. <i>Gene Therapy</i> , 2021, 28, 513-527.	2.3	146
370	Post-Transplant Cyclophosphamide and Tacrolimusâ€”Mycophenolate Mofetil Combination Governs CVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1173.	1.0	10
371	Facts and Hopes in Multiple Myeloma Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 4468-4477.	3.2	13
372	Novel Experimental Drugs for Treatment of Multiple Myeloma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 245-264.	1.5	16
373	Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 3549-3555.	3.2	51
374	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. <i>JCI Insight</i> , 2021, 6, .	2.3	18

#	ARTICLE	IF	CITATIONS
375	Industrializing engineered autologous T cells as medicines for solid tumours. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 476-488.	21.5	12
376	A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 377-389.	1.0	6
377	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. <i>Clinical Cancer Research</i> , 2021, 27, 3793-3803.	3.2	27
378	Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2018.	1.7	26
379	Pathway-Directed Therapy in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1668.	1.7	15
380	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
381	CT103A, a forward step in multiple myeloma immunotherapies. <i>Blood Science</i> , 2021, 3, 59-61.	0.4	3
382	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021, 2, 302-318.	2.6	40
383	Reactions Related to CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 663201.	2.2	54
384	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. <i>Journal of Hematology and Oncology</i> , 2021, 14, 66.	6.9	35
385	CAR T-cell therapy in multiple myeloma: more room for improvement. <i>Blood Cancer Journal</i> , 2021, 11, 84.	2.8	97
386	Role and Modulation of NK Cells in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 167-181.	0.2	5
387	Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. <i>Leukemia and Lymphoma</i> , 2021, 62, 2235-2241.	0.6	4
388	Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1686.	1.7	25
389	CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. <i>Gene Therapy</i> , 2021, 28, 560-571.	2.3	70
390	Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. <i>Gene Therapy</i> , 2023, 30, 411-420.	2.3	3
391	BCMA CARs in multiple myeloma: room for more?. <i>Blood</i> , 2021, 137, 2859-2860.	0.6	1
393	Minimal Residual Disease in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 247-255.	1.0	7

#	ARTICLE	IF	CITATIONS
394	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. <i>Cancers</i> , 2021, 13, 2712.	1.7	13
395	Neurological complications of cancer immunotherapy (CAR T cells). <i>Journal of the Neurological Sciences</i> , 2021, 424, 117405.	0.3	10
396	Hydrogel Scaffolds to Deliver Cell Therapies for Wound Healing. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 660145.	2.0	69
397	Expression of activated integrin $\alpha 2 \beta 1$ in multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 114, 3-7.	0.7	8
398	Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 205-212.	1.0	1
400	Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients. <i>Medicine (United States)</i> , 2021, 100, e25784.	0.4	3
401	Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and review of the literature. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 39-44.	2.0	18
403	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. <i>Kidney International Reports</i> , 2021, 6, 1416-1422.	0.4	17
404	Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature. <i>Frontiers in Medicine</i> , 2021, 8, 649824.	1.2	7
405	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
406	Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3002-3006.	3.3	26
407	A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. <i>Cellular Immunology</i> , 2021, 363, 104342.	1.4	11
408	Advances in Cellular Immunotherapy in Hematologic Malignancies. <i>Advances in Oncology</i> , 2021, 1, 223-236.	0.1	0
409	From VAD to VRD. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 190-195.	1.0	1
410	Induction Therapy Strategies in the Transplant-Ineligible Population. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 196-200.	1.0	1
411	Navigating CAR-T cells through the solid-tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 531-550.	21.5	236
412	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	10.6	315
413	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 286, 33-39.	2.0	6

#	ARTICLE	IF	CITATIONS
414	The Potential Role of the Intestinal Microenvironment and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
415	CAR T-cell therapy for multiple myeloma: state of the art and prospects. <i>Lancet Haematology</i> , 2021, 8, e446-e461.	2.2	75
416	CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e596.	1.2	11
417	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 741-751.	0.2	5
418	The gene regulatory network controlling plasma cell function. <i>Immunological Reviews</i> , 2021, 303, 23-34.	2.8	18
419	Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. <i>Frontiers in Immunology</i> , 2021, 12, 684642.	2.2	57
420	CAR T-Cell Therapy: An Update for Radiologists. <i>American Journal of Roentgenology</i> , 2021, 217, 1461-1474.	1.0	20
421	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e246-e265.	1.8	27
422	Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy. <i>Targeted Oncology</i> , 2021, 16, 503-515.	1.7	9
423	Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. <i>Cancers</i> , 2021, 13, 2853.	1.7	9
424	Engineering Gene Therapy: Advances and Barriers. <i>Advanced Therapeutics</i> , 2021, 4, 2100040.	1.6	23
425	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	1.8	3
427	Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function. <i>Current Medical Science</i> , 2021, 41, 474-481.	0.7	8
428	Multifaceted Role of the Transforming Growth Factor β^2 on Effector T Cells and the Implication for CAR-T Cell Therapy. <i>Immuno</i> , 2021, 1, 160-173.	0.6	4
429	KarMMA-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 116.	2.8	44
430	CAR-based cell therapy: evaluation with bibliometrics and patent analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4374-4382.	1.4	2
431	Sequencing of myeloma therapy: Finding the right path among many standards. <i>Hematological Oncology</i> , 2021, 39, 68-72.	0.8	6
432	New targets for CAR T therapy in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101277.	0.7	9

#	ARTICLE	IF	CITATIONS
433	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 120.	2.8	18
434	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	0.6	9
435	Extramedullary Plasmacytomas of the Oral Cavity: A Case Report and Review of the Literature. <i>Journal of Cancer & Allied Specialties</i> , 2021, 7, .	0.1	1
436	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	1.3	11
437	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1830-1842.	0.6	40
438	New era of personalized medicine: Advanced therapy medicinal products in Europe. <i>World Journal of Immunology</i> , 2021, 11, 1-10.	0.5	0
439	CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. <i>Stem Cell Research and Therapy</i> , 2021, 12, 374.	2.4	33
440	Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis. <i>Frontiers in Immunology</i> , 2021, 12, 638678.	2.2	11
441	IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. <i>Cancers</i> , 2021, 13, 3534.	1.7	19
442	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. <i>Clinical Cancer Research</i> , 2021, 27, 5376-5388.	3.2	14
443	Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021, 17, 405-413.	1.4	10
444	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 715-727.	12.5	136
445	Novel immunotherapies in multiple myeloma — chances and challenges. <i>Haematologica</i> , 2021, 106, 2555-2565.	1.7	21
447	A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. <i>Stem Cell Research and Therapy</i> , 2021, 12, 428.	2.4	63
448	A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. <i>British Journal of Haematology</i> , 2021, 195, 217-229.	1.2	1
449	The Clinical Application of Neoantigens in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703517.	1.3	8
450	In Situ Programming of CAR T Cells. <i>Annual Review of Biomedical Engineering</i> , 2021, 23, 385-405.	5.7	33
451	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	1.6	14

#	ARTICLE	IF	CITATIONS
452	Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 965-973.	1.9	13
453	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
454	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	1.0	2
455	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. , 2021, 9, e002410.		9
456	Toxicities associated with adoptive cellular therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101287.	0.7	9
457	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711
458	Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3912.	1.7	25
459	Clinical experience of CAR T cells for multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101306.	0.7	8
460	CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy. <i>Advanced Pharmaceutical Bulletin</i> , 2022, 12, 476-489.	0.6	2
461	NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100968.	2.7	5
462	Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma. <i>Current Opinion in Immunology</i> , 2021, 71, 117-123.	2.4	4
463	PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 665970.	2.2	24
464	Chimeric antigen receptor T-cells (CARs) in cancer treatment. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	1
465	Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 96-106.	2.0	11
466	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
467	B Cells in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 395-413.	0.8	12
468	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 169-180.	0.8	7
469	Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. , 2021, 9, e002303.		16

#	ARTICLE	IF	CITATIONS
470	NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 146.	2.8	67
471	Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. <i>Frontiers in Immunology</i> , 2021, 12, 720571.	2.2	25
472	Effective anti-BCMA retreatment in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 3016-3020.	2.5	30
473	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , 2021, 13, 4320.	1.7	11
474	Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T). <i>Cmaj</i> , 2021, 193, E1300-E1302.	0.9	2
475	Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. <i>Frontiers in Immunology</i> , 2021, 12, 717850.	2.2	10
476	Magic and mystery of microRNA-32. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8588-8601.	1.6	11
477	Targeting BCMA in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 367-383.	1.2	6
478	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
479	CAR T cells: Building on the CD19 paradigm. <i>European Journal of Immunology</i> , 2021, 51, 2151-2163.	1.6	43
480	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
481	On the road to eliminating long-lived plasma cells—are we there yet? <i>Immunological Reviews</i> , 2021, 303, 154-167.	2.8	13
482	The infection rate in new diagnosis and relapsed/refractory multiple myeloma patients who had bortezomib-based chemotherapy and relationship between development of infection and lymphocyte/monocyte ratio. <i>The European Research Journal</i> , 0, .	0.1	0
483	Engineering the next generation of CAR-NK immunotherapies. <i>International Journal of Hematology</i> , 2021, 114, 554-571.	0.7	37
484	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	1.7	6
485	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	3.2	18
486	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. <i>Immunologic Research</i> , 2021, 69, 471-486.	1.3	8
487	Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. <i>Leukemia</i> , 2022, 36, 790-800.	3.3	22

#	ARTICLE	IF	CITATIONS
488	Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. <i>EJHaem</i> , 0, , .	0.4	2
489	Polymeric nanomedicines targeting hematological malignancies. <i>Journal of Controlled Release</i> , 2021, 337, 571-588.	4.8	15
490	Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2045-2054.	2.5	46
491	Non-BCMA targeted CAR T cell therapies for multiple myeloma. <i>Immunomedicine</i> , 2021, 1, e1030.	0.7	2
492	Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. <i>Reproductive BioMedicine Online</i> , 2022, 44, 81-92.	1.1	6
493	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2
494	The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. <i>British Journal of Haematology</i> , 2022, 196, 488-506.	1.2	14
495	Pushing the boundaries of organs before it's too late: pre-emptive regeneration. <i>Transplant International</i> , 2021, 34, 1761-1769.	0.8	0
496	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	2.5	28
497	Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. <i>Cytotherapy</i> , 2021, 23, 820-832.	0.3	5
498	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
499	Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. , 2022, 232, 108007.		12
500	Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5290-5299.	2.5	40
501	Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. <i>Cancers</i> , 2021, 13, 4867.	1.7	8
502	Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. <i>Blood</i> , 2021, 138, 2686-2695.	0.6	11
503	Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?. <i>Cureus</i> , 2021, 13, e17709.	0.2	2
504	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	3.2	15
505	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27

#	ARTICLE	IF	CITATIONS
506	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
507	BCMA-Directed CAR T-Cells: Early Results and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S162-S165.	0.2	0
508	Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma. <i>Oncotarget</i> , 2021, 12, 2051-2067.	0.8	0
509	BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, 25-34.	1.2	8
510	CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. <i>Cancer Gene Therapy</i> , 2022, 29, 475-483.	2.2	38
511	BCMA in Multiple Myeloma—A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4088.	1.0	25
512	Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. <i>Molecular Cancer</i> , 2021, 20, 126.	7.9	86
513	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 156, 164-174.	1.3	9
514	Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow. <i>Journal of Controlled Release</i> , 2021, 339, 1-13.	4.8	4
515	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
516	Synthetic receptors for logic gated T cell recognition and function. <i>Current Opinion in Immunology</i> , 2022, 74, 9-17.	2.4	7
517	Immune Therapies for Hematologic Malignancies. <i>Cancers</i> , 2021, 13, 295.	1.7	0
518	Cellular Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 741-761.	0.0	0
519	Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. <i>Oncolmmunology</i> , 2021, 10, 1959102.	2.1	19
520	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. <i>Molecular Cancer</i> , 2021, 20, 5.	7.9	12
521	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e815-e821.	2.9	113
522	Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 215.	1.7	21
523	B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	24

#	ARTICLE	IF	CITATIONS
524	The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072110196.	1.1	8
525	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 2021, 13, 271.	1.7	39
526	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
527	Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110367.	1.1	28
528	Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics, 2021, 5, 90-112.	2.7	22
529	New regimens and directions in the management of newly diagnosed multiple myeloma. American Journal of Hematology, 2021, 96, 367-378.	2.0	8
530	Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases. Cell Transplantation, 2021, 30, 096368972110119.	1.2	11
531	Leveraging Immunotherapy with Nanomedicine. Advanced Therapeutics, 2020, 3, 2000134.	1.6	2
532	Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Cancer Medicine, 2021, 10, 563-574.	1.3	33
533	CAR T-Cells. Advances in Experimental Medicine and Biology, 2020, 1244, 215-233.	0.8	24
534	Emerging CAR landscape for cancer immunotherapy. Biochemical Pharmacology, 2020, 178, 114051.	2.0	6
535	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 178-188.	0.4	60
536	Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits. International Journal of Hyperthermia, 2020, 37, 18-33.	1.1	12
537	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
539	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
540	Immunotherapy of multiple myeloma. Journal of Clinical Investigation, 2020, 130, 1565-1575.	3.9	103
541	State of the art in CAR T cell therapy for CD19+ B cell malignancies. Journal of Clinical Investigation, 2020, 130, 1586-1594.	3.9	74
542	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. Journal of Clinical Investigation, 2020, 130, 1595-1607.	3.9	10

#	ARTICLE	IF	CITATIONS
543	The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097981.	1.1	18
544	CAR T-cell therapy: is it prime time in myeloma?. <i>Blood Advances</i> , 2019, 3, 3473-3480.	2.5	21
545	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	1.7	38
546	Designing high affinity target-binding peptides to HLA-E: a key membrane antigen of multiple myeloma. <i>Aging</i> , 2020, 12, 20457-20470.	1.4	5
547	A brief history of CAR-T cells: from laboratory to the bedside. <i>Acta Haematologica Polonica</i> , 2020, 51, 2-5.	0.1	32
548	CART Cell Toxicities: New Insight into Mechanisms and Management. <i>Clinical Hematology International</i> , 2020, 2, 149.	0.7	19
549	Cytokines in CAR T Cell-associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	2.2	110
550	Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 568056.	1.3	11
551	Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1302.	1.7	45
552	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
553	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	1.0	35
554	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	0.6	10
555	Defining and Managing High-Risk Multiple Myeloma: Current Concepts. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1730-1737.	2.3	21
556	Critical care management of chimeric antigen receptor T-cell therapy recipients. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 78-93.	157.7	29
558	A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 161.	6.9	90
559	Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. <i>Blood Cancer Journal</i> , 2021, 11, 168.	2.8	24
560	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. <i>Expert Review of Hematology</i> , 2021, , 1-14.	1.0	1
561	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8

#	ARTICLE	IF	CITATIONS
562	Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 138-148.	1.9	9
563	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4978.	1.7	6
564	A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. <i>Cancers</i> , 2021, 13, 5171.	1.7	7
565	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
566	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. <i>Cancers</i> , 2021, 13, 5154.	1.7	30
567	An Allogeneic Multiple Myeloma GM-CSFâ€“Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. <i>Clinical Cancer Research</i> , 2021, 27, 6696-6708.	3.2	8
568	Current Status of CAR-T Cell Therapy in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 660-671.	0.2	2
569	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 197, 28-40.	1.2	9
570	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. <i>Cells</i> , 2021, 10, 2845.	1.8	6
571	Chimeric antigen receptor Tâ€“cells, bispecific antibodies, and antibodyâ€“drug conjugates for multiple myeloma: An update. <i>American Journal of Hematology</i> , 2022, 97, 99-118.	2.0	23
572	Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. <i>Nanomaterials</i> , 2021, 11, 2792.	1.9	8
573	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5344-5348.	2.5	16
574	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , 2021, 158, 85-98.	1.3	16
575	Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2019, 15, 87.	0.2	2
576	III. Chimeric Antigen Receptor T-cell Immure Therapy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1375-1383.	0.0	0
578	Immunotherapeutic Strategies for Multiple Myeloma. , 2020, , 75-102.		0
579	Chimeric antigen receptor (CAR)-T cell therapy. <i>Okayama Igakkai Zasshi</i> , 2020, 132, 34-36.	0.0	0
580	Chimeric antigen receptor T in the treatment of multiple myeloma â€“ state of the art and future directions. <i>Acta Haematologica Polonica</i> , 2020, 51, 120-124.	0.1	0

#	ARTICLE	IF	CITATIONS
581	Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 460-466.	2.0	24
582	Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 755866.	2.2	18
583	Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101565.	3.9	4
584	Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. <i>Blood Advances</i> , 2022, 6, 672-678.	2.5	8
585	Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 539-550.	1.8	6
586	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells. <i>Cancers</i> , 2021, 13, 5435.	1.7	3
587	Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immuno-engineering. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 378-386.	2.0	1
588	Regulating innovation in the early development of cell therapies. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	2
589	REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021012.	0.5	5
592	Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. <i>Current Opinion in Immunology</i> , 2022, 74, 39-45.	2.4	13
594	Promising Preclinical Results for Immunotherapy in Multiple Myeloma. , 2020, 17, .		0
595	Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 301-305.	0.2	0
596	Aggressive Plasmablastic Myeloma With Extramedullary Cord Compression and Hyperammonemic Encephalopathy: Case Report and Literature Review. <i>Anticancer Research</i> , 2021, 41, 5839-5845.	0.5	2
597	Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. <i>Scientific Reports</i> , 2021, 11, 21902.	1.6	12
598	Direct N- or C-Terminal Protein Labeling Via a Sortase-Mediated Swapping Approach. <i>Bioconjugate Chemistry</i> , 2021, 32, 2397-2406.	1.8	4
599	Hematopoietic Stem Cells and Regeneration. <i>Cold Spring Harbor Perspectives in Biology</i> , 2022, 14, a040774.	2.3	3
601	CAR-T cells leave the comfort zone: current and future applications beyond cancer. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	5
604	The role of Wnt/ β -catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 9932-9949.	0.0	0

#	ARTICLE	IF	CITATIONS
605	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. <i>Current Research in Translational Medicine</i> , 2022, 70, 103320.	1.2	9
606	Single-cell atlas of splenocytes reveals a critical role of a novel plasma cell-specific marker Hspa13 in antibody class-switching recombination and somatic hypermutation. <i>Molecular Immunology</i> , 2022, 141, 79-86.	1.0	5
607	Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 724411.	2.2	3
608	CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. <i>EJHaem</i> , 2022, 3, 32-38.	0.4	16
609	Salvage therapy with daratumumab (Dara-CD20) in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2022, 40, 202-211.	0.8	9
610	Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 118.e1-118.e5.	0.6	4
611	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	0.8	2
612	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	3.3	18
613	Cell Therapy: Types, Regulation, and Clinical Benefits. <i>Frontiers in Medicine</i> , 2021, 8, 756029.	1.2	61
614	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12126.	1.8	8
615	Annotating BCMA Expression in Multiple Myelomas. <i>Molecular Pharmaceutics</i> , 2022, 19, 3492-3501.	2.3	7
616	Genome Instability in Multiple Myeloma: Facts and Factors. <i>Cancers</i> , 2021, 13, 5949.	1.7	17
617	Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 293-296.	2.5	4
618	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. <i>Future Oncology</i> , 2022, 18, 277-289.	1.1	20
619	T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. <i>Cancers</i> , 2021, 13, 6067.	1.7	9
620	CAR T Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 297-317.	0.8	4
621	Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 682-689.	0.8	3
622	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. <i>Cancer Drug Discovery and Development</i> , 2022, , 207-219.	0.2	1

#	ARTICLE	IF	CITATIONS
623	Engineered T cells and their therapeutic applications in autoimmune diseases. <i>Zoological Research</i> , 2022, 43, 150-165.	0.9	6
624	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. <i>Translational Oncology</i> , 2022, 16, 101309.	1.7	5
625	Jahrestagung der American Society of Hematology: Neue Optionen bei Rezidiven. , 0, , .		0
627	CAR-T cells, from principle to clinical applications. <i>Bulletin Du Cancer</i> , 2021, 108, S4-S17.	0.6	15
629	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
630	Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition. <i>Haematologica</i> , 2022, 107, 980-983.	1.7	3
631	Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 2135-2148.	2.3	3
632	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. <i>BMC Cancer</i> , 2022, 22, 98.	1.1	15
633	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 784024.	0.9	13
635	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. <i>Cytotherapy</i> , 2022, 24, 405-412.	0.3	6
636	Liposomal phytohemagglutinin: In vivo Tâ€cell activator as a novel panâ€cancer immunotherapy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 940-944.	1.6	7
637	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. <i>Biomedicines</i> , 2022, 10, 307.	1.4	9
639	Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications. <i>Frontiers in Oncology</i> , 2021, 11, 801851.	1.3	13
641	How I treat relapsed multiple myeloma. <i>Blood</i> , 2022, 139, 2904-2917.	0.6	16
642	Resistance and recurrence of malignancies after CAR-T cell therapy. <i>Experimental Cell Research</i> , 2022, 410, 112971.	1.2	4
643	Use of serum Bâ€cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. <i>Hematological Oncology</i> , 2022, 40, 243-248.	0.8	4
644	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22
645	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9

#	ARTICLE	IF	CITATIONS
646	Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.	0.4	7
647	CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. <i>Nature Communications</i> , 2022, 13, 587.	5.8	41
648	Manufacturing of CAR-T Cells: The Assembly Line. <i>Cancer Drug Discovery and Development</i> , 2022, , 121-139.	0.2	1
649	Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary/extrasosseous, extramedullary/bone related, and without extramedullary disease. <i>Hematological Oncology</i> , 2022, 40, 223-232.	0.8	9
650	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	0.6	53
651	Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. <i>Trends in Biotechnology</i> , 2022, 40, 875-890.	4.9	17
652	Targeting disialoganglioside GD2 with chimeric antigen receptor-redirection T cells in lung cancer. , 2022, 10, e003897.		27
653	A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	0.6	10
654	Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions. <i>Oncology and Therapy</i> , 2022, , 1.	1.0	0
655	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	3.8	308
656	Immunotherapeutic treatments for spinal and peripheral nerve tumors: a primer. <i>Neurosurgical Focus</i> , 2022, 52, E8.	1.0	1
657	Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 181-198.	1.8	14
658	Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. , 2022, , .		0
659	The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.. <i>Seminars in Oncology</i> , 2022, 49, 3-10.	0.8	3
660	A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell surface proteins on target cells. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	2
661	Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF- β . <i>Frontiers in Immunology</i> , 2022, 13, 832645.	2.2	13
662	Bryostatins Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytotoxicity of a Burkitt Lymphoma Cell Line. <i>Frontiers in Immunology</i> , 2022, 13, 825364.	2.2	6
663	T-SiGN tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice. <i>Oncolmmunology</i> , 2022, 11, 2029070.	2.1	5

#	ARTICLE	IF	CITATIONS
664	Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem cell transplantation for high-risk newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 537-547.	2.0	23
665	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. <i>Diagnostics</i> , 2022, 12, 409.	1.3	5
666	Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.	0.2	2
667	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	0.6	139
668	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021, 27, 2099-2103.	15.2	92
669	A human orthogonal IL-2 and IL-2R ¹ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. <i>Science Translational Medicine</i> , 2021, 13, eabg6986.	5.8	64
670	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. <i>Experientia Supplementum (2012)</i> , 2022, 113, 253-294.	0.5	1
671	A Phase I Study of C-CAR088, a Novel Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
672	Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy. <i>Scientific Reports</i> , 2022, 12, 2830.	1.6	2
673	CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
674	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	2.0	5
675	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
676	Rapid manufacturing of non-activated potent CAR T cells. <i>Nature Biomedical Engineering</i> , 2022, 6, 118-128.	11.6	92
677	Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells. <i>Anticancer Research</i> , 2022, 42, 1785-1799.	0.5	1
678	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	0.7	8
679	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol). <i>Open Research Europe</i> , 0, 2, 38.	2.0	1
680	Promising therapeutic approaches for relapsed/refractory multiple myeloma. <i>Hematology</i> , 2022, 27, 343-352.	0.7	4
682	Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. <i>Haematologica</i> , 2022, 107, 2395-2407.	1.7	7

#	ARTICLE	IF	CITATIONS
683	CAR T cell therapy for multiple myeloma: What have we learned?. <i>Leukemia</i> , 2022, 36, 1481-1484.	3.3	3
684	Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. <i>Stem Cell Research and Therapy</i> , 2022, 13, 112.	2.4	14
685	Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2246-2256.	0.8	43
686	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 304.e1-304.e9.	0.6	12
687	Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials. <i>Translational Cancer Research</i> , 2022, 11, 569-579.	0.4	4
688	Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021. <i>Frontiers in Immunology</i> , 2022, 13, 822004.	2.2	17
689	Genetic Modification of T Cells for the Immunotherapy of Cancer. <i>Vaccines</i> , 2022, 10, 457.	2.1	2
690	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
691	Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting. <i>Frontiers in Immunology</i> , 2022, 13, 839097.	2.2	4
692	sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1463-1471.	1.0	14
693	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
694	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1849-1860.	0.6	14
695	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	1.0	25
696	Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma. <i>Translational Oncology</i> , 2022, 20, 101413.	1.7	4
697	Chronic Kidney Disease in Cancer Survivors. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 469-476.e1.	0.6	5
698	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72
699	Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 299-304.	0.5	2
700	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. <i>Frontiers in Oncology</i> , 2021, 11, 783703.	1.3	4

#	ARTICLE	IF	CITATIONS
701	Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation. Hematology American Society of Hematology Education Program, 2021, 2021, 504-513.	0.9	4
703	The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers, 2022, 27, 22-34.	0.9	1
704	An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e392-e404.	0.2	13
705	CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia, 2022, 36, 1625-1634.	3.3	15
706	Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma. Clinical Cancer Research, 2022, 28, 2830-2843.	3.2	39
707	Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Molecular Therapy - Methods and Clinical Development, 2022, 25, 311-330.	1.8	33
709	Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nature Communications, 2022, 13, 2154.	5.8	25
710	Development of CAR T Cell Therapy in Children—A Comprehensive Overview. Journal of Clinical Medicine, 2022, 11, 2158.	1.0	12
711	BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs, 2022, 82, 613-631.	4.9	10
712	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. Advanced Drug Delivery Reviews, 2022, 185, 114301.	6.6	28
714	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2022, 101, 1217-1226.	0.8	2
715	Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma. HemaSphere, 2022, 6, e691.	1.2	5
716	Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances, 2023, 7, 768-777.	2.5	15
717	The need for uniform and coordinated practices involving centrally manufactured cell therapies. Journal of Translational Medicine, 2022, 20, 184.	1.8	5
721	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0
722	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. Cancer Treatment and Research, 2022, 183, 161-184.	0.2	2
723	Integrative lymph node-mimicking models created with biomaterials and computational tools to study the immune system. Materials Today Bio, 2022, 14, 100269.	2.6	9
724	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. Journal of Clinical Medicine, 2022, 11, 2513.	1.0	15

#	ARTICLE	IF	CITATIONS
725	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	1.9	18
726	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. <i>Cancer Research Communications</i> , 2022, 2, 330-341.	0.7	6
727	<scp>CARâ€”T</scp> cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status. <i>American Journal of Hematology</i> , 2022, 97, 933-941.	2.0	8
728	Tumour immunotherapy: lessons from predatorâ€”prey theory. <i>Nature Reviews Immunology</i> , 2022, 22, 765-775.	10.6	41
729	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
730	The CD8Î± hinge is intrinsically disordered with a dynamic exchange that includes proline cis-trans isomerization. <i>Journal of Magnetic Resonance</i> , 2022, 340, 107234.	1.2	5
731	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 25-37.	0.6	29
733	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	1.8	7
734	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	2.0	208
735	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
736	Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. <i>Molecular Therapy</i> , 2022, 30, 2537-2553.	3.7	32
737	Novel immunotherapies in multiple myeloma. <i>International Journal of Hematology</i> , 2022, 115, 799-810.	0.7	3
738	Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
739	T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. <i>Thyroid</i> , 2022, 32, 789-798.	2.4	3
740	Time 2EVOLVE: predicting efficacy of engineered T-cells â€” how far is the bench from the bedside?. , 2022, 10, e003487.		13
741	CAR-Tç»†èfžâœ”è†æ¶²ç³»ç»Ÿæ¶æ€šè,ç~æ²»ç—çš,,ç”ç©¶è¿›â±•. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University		
742	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. <i>Translational Oncology</i> , 2022, 22, 101459.	1.7	8
743	Moving Toward a Cure for Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	1.8	2

#	ARTICLE	IF	CITATIONS
744	BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. <i>Expert Review of Hematology</i> , 2022, 15, 503-517.	1.0	1
745	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> , 2022, 15, 519-537.	1.0	1
746	Immunotherapy in AL Amyloidosis. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1059-1071.	1.3	3
747	CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through. <i>International Reviews of Immunology</i> , 2022, 41, 567-581.	1.5	1
748	Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective. <i>Journal of Clinical Oncology</i> , 2022, 40, 3501-3509.	0.8	9
749	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	3.1	8
750	Next Generation Natural Killer Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
751	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
752	Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. <i>Regenerative Therapy</i> , 2022, 21, 34-36.	1.4	2
753	V β 9V γ 2 T cells expressing a BCMA-specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. <i>PLoS ONE</i> , 2022, 17, e0267475.	1.1	5
754	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	55
756	Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies. <i>Current Oncology</i> , 2022, 29, 4464-4477.	0.9	11
757	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development. <i>Clinical and Translational Science</i> , 2022, 15, 2057-2074.	1.5	9
758	The Past, Present, and Future of Non-Viral CAR T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39
759	Quantitative Clinical Pharmacology of CAR T-Cell Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 11-15.	2.3	2
760	CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment. <i>EJHaem</i> , 2022, 3, 970-974.	0.4	8
761	Multiple Myeloma: Possible Cure from the Sea. <i>Cancers</i> , 2022, 14, 2965.	1.7	4
762	CRISPR: A Promising Tool for Cancer Therapy. <i>Current Molecular Medicine</i> , 2022, 22, .	0.6	0

#	ARTICLE	IF	CITATIONS
763	Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 0, , .	0.8	0
764	Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1171-1183.	1.9	4
765	Transplant Onconephrology in Patients With Kidney Transplants. <i>Advances in Chronic Kidney Disease</i> , 2022, 29, 188-200.e1.	0.6	4
766	Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7046.	1.8	19
767	Natural killer cell homing and trafficking in tissues and tumors: from biology to application. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	64
768	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3230.	1.7	23
769	Targeting the Microenvironment for Treating Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7627.	1.8	9
770	CAR T cell therapy in advanced Bâ€ALL with heavy disease burden. <i>Immunomedicine</i> , 0, , .	0.7	0
771	NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma. <i>Blood Advances</i> , 2022, 6, 5152-5159.	2.5	13
772	EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects. <i>Molecular Therapy</i> , 2022, 30, 3358-3378.	3.7	2
773	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2757-2769.	1.2	4
774	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 915-926.	1.1	12
775	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	2.5	20
776	Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. <i>Immunological Investigations</i> , 2022, 51, 2215-2225.	1.0	5
777	Stem cell like memory T cells: A new paradigm in cancer immunotherapy. <i>Clinical Immunology</i> , 2022, 241, 109078.	1.4	12
778	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. <i>OncoTargets and Therapy</i> , 0, Volume 15, 799-813.	1.0	3
779	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
780	High-Throughput CRISPR Screening in Hematological Neoplasms. <i>Cancers</i> , 2022, 14, 3612.	1.7	3

#	ARTICLE	IF	CITATIONS
781	Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling. <i>Cancer Immunology Research</i> , 2022, 10, 1069-1083.	1.6	5
782	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 727-736.	0.6	5
784	Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
785	Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	47
786	CyBorD-DARA in newly diagnosed transplant-eligible multiple myeloma: results from the 16-BCNI-001/CTRIAL-IE 16-02 study show high rates of MRD negativity at end of treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	1
788	Treatment horizon in multiple myeloma. <i>European Journal of Haematology</i> , 2022, 109, 425-440.	1.1	6
789	Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma. <i>Cancers</i> , 2022, 14, 3507.	1.7	2
790	MULTIPLE MYELOMA: NARRATIVE REVIEW. , 2022, , 102-104.		0
791	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. <i>Current Opinion in Critical Care</i> , 2022, 28, 540-550.	1.6	5
792	Multiple Myeloma Therapy: Emerging Trends and Challenges. <i>Cancers</i> , 2022, 14, 4082.	1.7	19
793	CAR T cells in multiple myeloma: Where we stand and where we might be going. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	0
795	Chimeric Antigen Receptor-T Cell Therapy. <i>Korean Journal of Medicine</i> , 2022, 97, 229-237.	0.1	0
796	A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 4663.	1.0	1
797	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
798	A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. <i>Cancers</i> , 2022, 14, 3796.	1.7	3
799	Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
800	Bispecific Antibodies for the Treatment of Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 286-297.	1.2	4
801	Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy. <i>Chinese Medical Journal</i> , 2022, 135, 1639-1641.	0.9	4

#	ARTICLE	IF	CITATIONS
802	Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 6109-6119.	2.5	23
803	Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
804	Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	18
805	GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay. <i>Biochemistry and Biophysics Reports</i> , 2022, 31, 101324.	0.7	3
806	Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. , 2022, 10, e004854.		8
807	Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	3
808	Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
809	Applying a clinical lens to animal models of CAR-T cell therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 17-31.	1.8	18
810	CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 119-136.	1.2	15
811	T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. <i>Cancers</i> , 2022, 14, 4249.	1.7	2
812	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
813	Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. <i>Clinical Cancer Research</i> , 2022, 28, 5156-5166.	3.2	10
814	Adoptive Cell Therapy Using Genetically Engineered T Cells to Target CEA, Calcitonin, and <i>RET</i> M918T in Medullary Thyroid Cancer Cells. <i>Clinical Thyroidology</i> , 2022, 34, 412-416.	0.0	0
815	All-trans retinoic acid works synergistically with the $\hat{\beta}$ -secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. <i>Haematologica</i> , 2023, 108, 568-580.	1.7	7
816	Transcriptional states of CAR-T infusion relate to neurotoxicity â€“ lessons from high-resolution single-cell SOM expression portraying. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
817	Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
818	Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	15
819	Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. , 2022, 10, e004567.		3

#	ARTICLE	IF	CITATIONS
820	CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. <i>Nature Communications</i> , 2022, 13, .	5.8	35
821	The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. <i>BioDrugs</i> , 2022, 36, 773-780.	2.2	6
822	Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1455-1476.	2.0	8
823	Rethinking cancer targeting strategies in the era of smart cell therapeutics. <i>Nature Reviews Cancer</i> , 2022, 22, 693-702.	12.8	21
824	Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma. <i>AAPS Journal</i> , 2022, 24, .	2.2	2
825	Steps towards a Multiple Myeloma Cure?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1451.	1.1	3
826	lofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	5
827	Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. <i>Leukemia</i> , 2022, 36, 2596-2604.	3.3	17
828	Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. , 2022, 10, e005145.		9
829	CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. <i>Science Advances</i> , 2022, 8, .	4.7	19
830	Realâ€world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study. <i>British Journal of Haematology</i> , 2023, 200, 45-53.	1.2	16
831	Impact of cryopreservation on CAR T production and clinical response. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
832	BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Cancer Letters</i> , 2023, 553, 215949.	3.2	11
833	Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. <i>Haematologica</i> , 2023, 108, 1827-1839.	1.7	7
834	CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211320.	0.8	9
835	Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	5
836	The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2023, 64, 261-272.	0.6	2
837	NK cell therapy in relapsed refractory multiple myeloma. <i>Clinical Immunology</i> , 2023, 246, 109168.	1.4	2

#	ARTICLE	IF	CITATIONS
838	Bispecific antibodies in multiple myeloma treatment: A journey in progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	17
839	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
840	Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. <i>Cancer Cell</i> , 2022, 40, 1407-1422.e7.	7.7	27
842	Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. <i>Blood</i> , 2023, 141, 835-845.	0.6	11
843	BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. <i>Haematologica</i> , 2023, 108, 958-968.	1.7	11
844	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
845	Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities. <i>Xenobiotica</i> , 2022, 52, 840-854.	0.5	3
846	Immunotherapy for the treatment of multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
847	Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
849	Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti" B-Cell Maturation Antigen Chimeric Antigen Receptor" T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). <i>Journal of Clinical Oncology</i> , 2023, 41, 1275-1284.	0.8	15
850	Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. , 2022, 10, e005091.		11
851	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	19
852	Radioimmunoconjugates in the age of modern immuno-oncology. <i>Life Sciences</i> , 2022, 310, 121126.	2.0	3
853	Novel and Experimental Clone-Directed Therapies. , 2022, , 355-376.		0
854	Rebooting the Myeloma Treatment Programme. <i>European Medical Journal Hematology</i> , 0, , 36-43.	0.0	0
855	Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic. <i>Clinical Cancer Research</i> , 2023, 29, 843-857.	3.2	4
856	Expression levels and patterns of B" cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 462-470.	0.7	1
857	Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	11

#	ARTICLE	IF	CITATIONS
858	Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 179-185.	0.8	4
859	BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	25
860	Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox. <i>Cancers</i> , 2022, 14, 5657.	1.7	4
861	Gene and Cell Therapy: How to Build a BioDrug. <i>Pediatric Oncology</i> , 2022, , 51-88.	0.5	0
862	A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy. <i>International Immunopharmacology</i> , 2023, 114, 109592.	1.7	1
863	Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114061.	2.5	1
864	What matters most to patients with multiple myeloma? A Pan-European patient preference study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
865	Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. <i>Nature Communications</i> , 2022, 13, .	5.8	18
866	Multiplexed engineering and precision gene editing in cellular immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
867	Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e182-e189.	0.2	0
868	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. <i>Oncolimmunology</i> , 2023, 12, .	2.1	7
869	Dose-“response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15
870	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
871	The emerging therapeutic landscape of relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2023, 102, 1-11.	0.8	12
872	Phase I CAR-T Clinical Trials Review. <i>Anticancer Research</i> , 2022, 42, 5673-5684.	0.5	0
873	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	1.8	4
874	SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
875	Dasatinib for treatment of CAR T-cell therapy-related complications. , 2022, 10, e005956.		10

#	ARTICLE	IF	CITATIONS
876	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
877	Novel modular chimeric antigen receptor spacer for T cells derived from signal regulatory protein alpha Ig-like domains. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	2
878	Immunotherapy for Esophageal Cancer. , 2023, , 1-22.		0
879	Current Developments in the Preclinical and Clinical use of Natural Killer T cells. <i>BioDrugs</i> , 2023, 37, 57-71.	2.2	4
880	Current state of CAR-T therapy for T-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211430.	1.1	11
881	Chimeric antigen receptor T cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 275-285.	157.7	24
883	A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma. <i>Modern Pathology</i> , 2023, 36, 100050.	2.9	2
884	Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 2087-2097.	0.8	67
885	Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
887	Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. <i>Journal of the Egyptian National Cancer Institute</i> , 2022, 34, .	0.6	1
888	Chimeric antigen receptor T (CAR) cells: Novel cell therapy for hematological malignancies. <i>Cancer Medicine</i> , 2023, 12, 7844-7858.	1.3	15
889	Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 645.	1.8	4
890	How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> , 2023, 15, 155.	1.7	3
891	Tumor immunology. , 2023, , 245-452.		0
892	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
893	Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. <i>International Journal of Hematology</i> , 2023, 117, 729-737.	0.7	1
894	A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
896	Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells. <i>Chinese Medical Journal</i> , 2023, 136, 127-137.	0.9	3

#	ARTICLE	IF	CITATIONS
897	GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. <i>Lancet Haematology</i> , 2023, 10, e107-e116.	2.2	36
898	Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1687-1697.	1.3	3
899	Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. <i>Cancer Discovery</i> , 2023, 13, 829-843.	7.7	23
900	Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model. <i>Cancer Medicine</i> , 2023, 12, 12569-12580.	1.3	1
901	Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 430-437.	0.6	15
902	A second-generation CD38-CAR-T cell for the treatment of multiple myeloma. <i>Cancer Medicine</i> , 0, , .	1.3	1
903	Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2573-2583.	2.0	0
904	T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma. <i>Cytotherapy</i> , 2023, 25, 490-501.	0.3	0
905	Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114609.	2.5	4
906	Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. <i>Cytotherapy</i> , 2023, 25, 653-658.	0.3	3
908	Biology and status of chimeric antigen receptor-engineered T cell therapy. , 2023, , 149-165.		0
910	Immunotherapy for Hematological Cancers. , 2023, , 1-15.		0
911	Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. <i>EJHaem</i> , 2023, 4, 184-191.	0.4	0
912	Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 699-712.	0.5	5
913	Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. <i>Current Treatment Options in Oncology</i> , 2023, 24, 184-211.	1.3	6
914	Massively parallel knock-in engineering of human T cells. <i>Nature Biotechnology</i> , 2023, 41, 1239-1255.	9.4	11
916	SOHO State-of-the-Art Updates and Next Questions BCMA-Directed CAR T-Cells: Early Results and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 310-321.	0.2	3
917	The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma. <i>BMC Cancer</i> , 2023, 23, .	1.1	1

#	ARTICLE	IF	CITATIONS
918	Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T cell therapy recipients. <i>Cancer Medicine</i> , 2023, 12, 9228-9235.	1.3	7
919	Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
920	Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2023, 388, 1002-1014.	13.9	123
921	Applying single-cell highly multiplexed secretome proteomics to characterize immunotherapeutic products and predict clinical responses. <i>Proteomics</i> , 2023, 23, .	1.3	2
922	Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. <i>Haematologica</i> , 0, , .	1.7	2
923	Racing CARs to veterinary immuno-oncology. <i>Frontiers in Veterinary Science</i> , 0, 10, .	0.9	0
924	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. <i>Biomolecules</i> , 2023, 13, 382.	1.8	8
925	CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	15
926	Emerging roles of the gut microbiota in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
927	CAR immune cells: design principles, resistance and the next generation. <i>Nature</i> , 2023, 614, 635-648.	13.7	96
928	Deconvolution of clinical variance in CAR-T cell pharmacology and response. <i>Nature Biotechnology</i> , 2023, 41, 1606-1617.	9.4	9
929	Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	2
930	Chimeric antigen receptor T cells therapy in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 2279-2296.	1.2	2
931	A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 147-172.	0.8	5
932	Anti-CD137 Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 2583-2593.	0.8	17
933	Current Status and Perspective of CAR-T Cell Therapy for Hematological Cancers. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 633-639.	0.0	0
934	Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. <i>Nature Biotechnology</i> , 2023, 41, 1618-1632.	9.4	15
936	The BAFF-APRIL System in Cancer. <i>Cancers</i> , 2023, 15, 1791.	1.7	8

#	ARTICLE	IF	CITATIONS
937	Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. <i>Annals of Hematology</i> , 2023, 102, 1269-1270.	0.8	2
938	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. <i>Cancers</i> , 2023, 15, 1989.	1.7	2
939	Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	0
940	Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review. <i>Clinical Hematology International</i> , 2023, 5, 122-129.	0.7	4
941	Management of Relapsedâ€“Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. <i>Cancers</i> , 2023, 15, 2160.	1.7	3
942	Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in <i>Komagataella phaffii</i> with stimulatory activity for Natural Killer cells. <i>Microbial Cell Factories</i> , 2023, 22, .	1.9	0
943	Long-term outcomes following CAR T cell therapy: what we know so far. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 359-371.	12.5	119
944	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
945	Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature. <i>Biomedicines</i> , 2023, 11, 1225.	1.4	1
962	Chimeric Antigen Receptor Therapy in Multiple Myeloma. , 2024, , 309-329.		0
976	Applications of synthetic biology in medical and pharmaceutical fields. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	17
985	Biomarkers in Precision Medicine with Special Reference to Oncology. , 2023, , 173-187.		0
995	History, Evolution, Milestones in Cancer Research and Treatment. , 2023, , 1-29.		0
1004	Engineering Nanobody Targeting Cancer Stem Cells. , 2023, , 255-269.		0
1014	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
1027	BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. <i>Annals of Hematology</i> , 0, , .	0.8	1
1041	Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1059	Stem Cell-Derived Cell Therapy for Cancer. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
1063	Early mortality after chemotherapy as a quality indicator—the leukemia perspective. Blood Cancer Journal, 2023, 13, .	2.8	0
1103	Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer Journal, 2024, 14, .	2.8	1
1112	Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies. , 2024, , .		0
1126	Immunotherapy of Solid Tumors Based on Neoantigen Vaccines. , 2024, , 1-19.		0